Testing new drugs for tumors caused by NF2-related schwannomatosis
Original title: Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, testing both safety and whether the drugs help.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether new drugs can help people with NF2-related schwannomatosis, a condition that causes tumors in the nerves and brain.
Who this trial is for. This trial is for people with NF2-related schwannomatosis, also called NF2-SWN. It tests new drugs and drug combinations across four tumor types tied to this condition: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas. The drug groups running now are selumetinib, and luvometinib with serplulimab.
Where it stands. This trial has not reported results. It is set up to look at how safe these drugs are and whether they help. Some people in the study get routine care and follow-up without a study drug. That group is used for comparison. The trial is built so drug groups can be added or stopped as information comes in. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If you have NF2-related schwannomatosis, this is one place researchers are testing new options. You could bring it up with your care team and ask if it might fit your situation. They can help you weigh it against the care you are getting now.
What it doesn't mean: This does not mean these drugs work. A trial is a test, not a proven treatment. Joining a study is not a guarantee that you will be helped, and some people get routine care without a study drug. This is not a cure, and no one can promise you a place in the study.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.